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Inhaled corticosteroids are highly effective in the treatment of asthma at all ages and their use in younger 
children is increasing. As concerns exist about the long-term systemic side-effects of high dose inhaled 
corticosteroids, current guidelines continue to recommend sodium cromoglycate (SCG) as first line regular 
medication for children with frequent symptoms. Few published studies have compared the safety and 
efficacy of inhaled corticosteroids with SCG in children. This study compares SCG with the new inhaled 
corticosteroid, fluticasone propionate (FP), which has theoretical advantages over other currently available 
corticosteroids due to its negligible oral bioavailability. 
This was a randomized, open, multi-centre, parallel group comparison of 5Opg FP twice daily and 
20 mg SCG four times daily over 8 weeks, preceded by a 2-week baseline period. Sixty-two general practices 
and two hospital centres enrolled 225 asthmatic children aged 4-12 years (110 received FP; 115 received SCG). 
Outcome measures improved in both groups, with a significant difference in favour of FP for the key variables 
of mean morning and evening % predicted PEFR and % of symptom-free days and nights. No significant 
difference was observed for FEV,, or relief medication use. Two children taking FP and 10 children taking 
SCG withdrew because of adverse events. 
This study showed that low dose FP was effective and superior to SCG in young children with 
mild-moderate asthma. Safety studies of longer duration are needed before changing the current recommen- 
dations for inhaled corticosteroid therapy. 
Introduction 
Inhaled corticosteroids are highly effective in the 
treatment of moderate and severe asthma at all ages 
and their use in younger children is increasing. Effects 
on function of the hypothalamic-pituitary-adrenal 
(HPA) axis can be detected when inhaled corticoster- 
oids are given at doses of 400 pug day- ’ (or greater) 
and at the moment there is little information about 
possible long-term systemic effects in children who 
start treatment with inhaled corticosteroids in 
infancy or the pre-school years (l-3). For these 
reasons, the recently published international con- 
sensus on the management of childhood asthma 
continues to recommend sodium cromoglycate 
(SCG) as the first line regular medication for children 
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with frequent symptoms (4). The current recommen- 
dations for inhaled corticosteroid therapy are for 
children who fail to respond to or comply with SCG 
therapy, or have severe asthma. The efficacy and 
safety of SCG are well established and this drug 
will provide good asthma control in about 60% of 
children with frequent symptoms (5,6). There are few 
published studies which have compared the safety 
and efficacy of inhaled corticosteroids with SCG in 
children (7-13). 
Fluticasone propionate (FP) is a new inhaled cor- 
ticosteroid currently under investigation. Preliminary 
work indicates it is a strong agonist at the gluco- 
corticoid receptor conferring potent topical activity 
(14). Oral bioavailability is negligible (~1%) (15). 
This is attributed to incomplete gastrointestinal 
absorption and virtually complete hepatic first pass 
metabolism to the inactive 17+carboxylic acid. 
Although currently available inhaled corticosteroids 
in doses up to 400 pug day - i are clinically safe, some 
children with more severe asthma may require life 
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long prophylaxis, perhaps starting in very early child- 
hood. There is the possibility of long-term effects on 
bone metabolism (16) but FP, with its negligible oral 
bioavailability and improved safety margin, does 
have theoretical advantages over the currently avail- 
able inhaled corticosteroids, particularly in young 
children. A study of short-term growth, as measured 
by knemometry, confirmed that FP had a sig- 
nificantly lower systemic effect than the clinically 
equivalent dose of beclomethasone dipropionate (17). 
Large multi-centre studies, conducted for regulatory 
purposes in asthmatic children, have found FP to be 
superior to placebo (18) and have suggested its 
clinical potency to be double that of beclomethasone 
dipropionate (19). The aim of this study was to 
compare the efficacy and tolerability of inhaled FP 
with SCG in children who had previously received 
only intermittent treatment with broncho- 
dilators, and who were receiving regular inhaled 
medication for the first time. 
Methods 
TRIAL DESIGN 
This was a multi-centre, open, randomized, parallel 
group study comprising a 2-week baseline period and 
an 8-week treatment period in which 20 mg SCG four 
times daily was compared with 5Opg FP twice daily. 
Asthmatic children aged 4-12 years who had pre- 
viously received only intermittent bronchodilator 
therapy and had never been treated with inhaled SCG 
or an inhaled corticosteroid, but who, on clinical 
grounds, were being considered for regular treatment, 
were recruited into the baseline assessment period. 
The diagnosis of asthma was based on clinical history 
which included recurrent episodes of wheeze and 
cough which had responded to bronchodilator 
therapy. Children who had received oral corticoster- 
oids in the previous 6 weeks or who had been given 
more than three short courses of systemic corticoster- 
oid therapy in the previous 6 months were not in- 
cluded. Children who had suffered a respiratory tract 
infection in the preceding 2 weeks were also excluded. 
Before commencement of the baseline assessment, 
forced expiratory volume in 1 s (FEV,) was recorded 
by spirometry. Peak expiratory flow rate (PEFR) was 
measured with a mini-Wright peak-flow meter after 
inhalation of 400 pg of salbutamol, in order to estab- 
lish the maximum achievable PEFR. Children were 
taught to use the mini-Wright peak-flow meter and 
were only included in the study if they could demon- 
strate its correct use. Each child was given the 
appropriate meter according to age and baseline 
peak-flow (either a standard or low reading meter). 
They were asked to record the best of three blows 
each morning and evening and use the same meter 
throughout the trial. Current bronchodilator medi- 
cation was replaced by salbutamol administered by 
the RotahalerTM device to be taken as required. 
Eligibility for the treatment period was determined 
during the 2-week baseline period. Symptoms of 
cough, wheeze, disturbance of sleep or daytime activ- 
ity, morning and evening PEFR and use of relief 
medication were recorded daily on diary cards at 
home. Children entered the treatment period if, on at 
least 7 days of the baseline period, they had reported 
asthma symptoms requiring one or more doses of 
inhaled salbutamol, or had recorded morning PEFRs 
of less than 80% of their maximum. 
The children who fulfilled the entry criteria were 
then randomly allocated to receive either 20 mg SCG 
four times daily by capsule powder device, or 
5Opg FP twice daily by DiskhalerTM device. Ran- 
domization was in balanced blocks of six, with each 
centre allocated at least one block. 
The children continued to take 2004OOpg sal- 
butamol by Rotahaler for symptomatic relief. They 
and their parents continued to make recordings on 
diary cards at home as in the baseline period. Each 
child was reviewed after 2 weeks, 5 weeks and on 
completion of the 8 weeks’ treatment. At each visit, 
the diary card was collected and replaced with a new 
one. Inhaler techniques were checked. 
The oropharynx was examined and swabs taken if 
clinically indicated. FEV, was measured by spiro- 
metry. Compliance with treatment was assessed by 
discussion with parents and from medication records 
in the patients’ diary cards. Adverse events and 
concomitant illness were documented. 
The protocol used was designed by the authors. 
The study was conducted by the Clinical Research 
Department of Allen & Hanburys Limited, through 
the collaboration of their Clinical Research Scientists 
and the participating physicians. As the intention was 
to recruit children who had never received regular 
medication, the trial was almost entirely based in 
general practices. The results and statistical analysis 
were independently reviewed by the Department of 
Applied Statistics at Reading University and by the 
authors. 
The study was approved by the Ethics Committee 
of each participating centre, and written informed 
consent to participate in the study was obtained from 
the parent or legal guardian of each child. The study 
was conducted in accordance with the Declaration of 
Helsinki (as revised in Hong Kong, 1989) and with 
Good Clinical Practice guidelines as issued by the 
European Community (1990). 
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STATISTICAL ANALYSIS 
The primary variable for comparing the efficacy of 
treatments was the change (from baseline) in mean 
morning % predicted PEFR at O-2, 2-5, and 5-8 
weeks’ treatment. If the smallest mean difference in 
change of % predicted PEFR of clinical relevance 
between the groups is 5%, then assuming a SD com- 
mon to both groups of 11% of predicted and 5% 
two-tailed significance, approximately 100 evaluable 
patients were required in each treatment group for a 
test at 90% power. PEFR data were expressed as the 
percentage of the patients’ predicted values related to 
height (20) and were analysed by multi-variate analy- 
sis of variance. For the secondary variables, change 
from baseline FEV, (expressed as % predicted) at the 
end of the treatment period was compared between 
the treatment groups using the student’s t-test; the 
percentage of days and nights on which the children 
were symptom-free and the frequency of use of relief 
medication were derived from the diary cards, and 
z-tests, i.e. using the normal distribution, were used 
to compare treatments at each time point. The 
student’s t-test was used to test for differences 
between the two treatment groups in mean % 
predicted morning PEFR at baseline. The level of 
significance for all analyses was taken to be PcO.05. 
Confidence intervals were calculated at the 95% level. 
Results 
Three hundred and five asthmatic children were 
recruited from 62 general practices and 2 hospital 
centres. Two hundred and twenty-five of them ful- 
filled the baseline entry criteria and entered the 
treatment period. One hundred and fifteen received 
SCG and 110 received FP. Although none had 
received regular medication, many were experiencing 
frequent symptoms but there were no obvious demo- 
graphic differences nor statistically significant differ- 
ences in asthma severity between the two treatment 
groups (Table 1). 
There was a significant difference in morning 
PEFR in favour of FP during the treatment period. 
Multi-variate analysis of variance showed that the 
treatment difference changed over time, increasing to 
7.5% of predicted at 68 weeks (P=O.OOOl). At this 
time, the 95% confidence interval showed that the 
true difference in favour of FP was likely to be at 
least 3.8% and could be as much as 11.2% of 
predicted. The difference for evening PEFR also 
favoured FP but only in the latter part of the 
treatment period, reaching a maximum of 5.6% of 
predicted during the last 2 weeks. The 95% 
Table I Baseline patient data 
Fluticasone Sodium 
propionate cromoglycate 
Number 110 115 
Male 64 66 
Female 46 49 
Age (years) Mean 8.5 7.9 
Range 4.1-12.7 4.1-12.9 
Proportion of: 
Symptom-free days (median) 0.14 0.15 
Symptom-free nights (median) 0.46 0.46 
Relief medication: 
Mean doses day ’ (SD) 1.97 (1.37) 1.91 (1.25) 
Mean doses night ’ (SD) 0.50 (053) 0.61 (0.62) 
PEFR (mean o/o predicted) 
Morning (SD) 93.1 (21.6) 89.9 (20.6) 
Evening (SD) 97.6 (23.5) 93.1 (21.3) 
FEV, (mean % predicted) (SD) 79 1 (16.3) 77.8 (16.7) 
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Fig. I Mean PEFR (SE) expressed as % of predicted, (a) 
morning, (b) evening. n , Fluticasone propionate (n = 110); 
A, Sodium cromoglycate (n= 115); *P<O.O5; t&0.01; 
3 P<0~0001. 
confidence interval was 2.3-9.0% of predicted; 
P=O.OOll at 6-8 weeks (Fig. 1). 
In both groups, FEV, improved during treatment. 
With FP, mean % predicted FEV, increased from 
366 J. F. Price and P. H. Weller 
”  
Baseline l-2 3-5 6-8 
Duration of treatment (weeks) 
100 I 
(b) 
80 t - 3 60 F .# 
rl 
Baseline 1-2 
Duration of treatment (weeks) 
* * 
~ 
3-5 6-8 
7 
Fig. 2 Median percentage of symptom-free days (a) and 
nights (b) for each period of assessment during the study. 
Solid bar, fluticasone propionate; Open bar, sodium 
cromoglycate; *P<O.O5. 
79.1 (SD 16.3) to 87.8 (SD 16.6%) of predicted and 
with SCG, the increase was from 77.8 (SD 16.7) to 
82.4 (SD 16.1)% of predicted. There was no evidence 
of a difference between treatments (P=O.27). 
During the 2-week baseline period, the children 
had frequent symptoms and required bronchodilator 
treatment on most days. The median percentage of 
symptom-free days was about 15%, and symptom- 
free nights about 45%. The percentage of symptom- 
free days increased markedly on both treatments. 
The median percentages reached 84% with FP and 
62% with SCG in the last 2 weeks. Symptom-free 
nights increased to 95% with FP and to 84% with 
SCG. There was a difference in favour of FP for the 
percentage of symptom-free nights at 3-5 weeks and 
at 6-8 weeks, and for the percentage of symptom-free 
days at 68 weeks (in all three cases, P<O.OS). Point 
estimates suggest that this difference could represent 
at least two more symptom-free days and nights with 
FP than with SCG in the last 3 weeks of the 
treatment period (Fig. 2). The requirement for relief 
medication declined in both treatment groups with 
no obvious difference between the two (Table 2). 
Table 2 Relief medication -mean number of doses of 
salbutamol 
Fluticasone Sodium 
propionate cromoglycate 
JW Night Day Night 
Baseline 1.91 0.50 1.91 0.61 
Weeks l-2 0.78 0.20 0.97 0.35 
Weeks 3-5 0.60 0.14 0.74 0.28 
Weeks 68 0.49 0.09 0.64 0.21 
Table 3 Adverse events leading to withdrawal from the 
study 
Number of patients 
Fluticasone Sodium 
propionate cromoglycate 
Adverse events (n=llO) (n=115) 
Exacerbation of asthma 1 1 
Acute chest pain 1 
Breathless and wheeze 1 
Burning sensation in chest 1 
Sore threat 1 
Stevens-Johnson syndrome 1 
Medication-induced coughing 1 
Medication-induced sickness 2 
Unacceptable taste of 2 
medication 
Total no. of patients who 2 10 
withdrew due to an adverse 
event 
Of the 225 patients who entered the treatment 
period, 37 (16%) withdrew, 11 from the FP group 
and 26 from the SCG group. Twenty-five with- 
drew for reasons which appeared to be unrelated 
to the treatment. Two children taking FP and 10 
children taking SCG withdrew because of adverse 
events (Table 3). Hoarse voice and oropharyngeal 
candidiasis were not observed in any of the children. 
Discussion 
Treatment with FP was superior to SCG for the 
primary variable, morning PEFR, and for the sec- 
ondary variables of evening PEFR and symptom-free 
days and nights. The mean difference between treat- 
ments of 7.5% of predicted in morning PEFR is likely 
to be of clinical importance in terms of asthma 
management, as is an increase of 2 symptom-free 
days per 3 weeks. Additional analysis showed that 
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the improvement during treatment with SCG was 
significant (mean morning % predicted PEFR 
increased 7.8%; 95% CI 5.3-10.2; P<O.OOOl). How- 
ever, the study was not placebo-controlled and some 
or all of the effect could be attributable to the ‘clinical 
trial effect’ (21). With a treatment period of 8 weeks, 
it is possible that neither therapy had reached its 
maximal effect, but there was no indication from the 
data that a longer treatment period would have 
changed the direction of the treatment difference. 
For practical reasons, the study was conducted in 
an open fashion. As the two drug treatments look 
very different and the frequency of administration 
varies, the only way to make the study blind would 
have been to use a double dummy technique. The 
requirement for the children to take two separate 
inhaled treatments would probably have affected 
both recruitment and compliance. The ‘clinical trial 
effect’ was likely to have been similar with both 
treatments since these children had never received 
regular inhaled medication before, so both would 
represent a ‘new’ form of therapy. The primary 
variable was an objective measure of lung function. 
The statistical analysis was done by a department 
who had no clinical involvement with the patients, 
and assessed by an independent university statistics 
department. 
Compliance with treatment could have influenced 
the results. It has been shown that compliance with 
four times a day administration is poorer than com- 
pliance with twice daily administration of inhaled 
therapy. On the basis of recorded medication use 
in diary cards during treatment, 23 patients 
(20 SCG:3 FP) were judged to have taken less than 
75% and one patient (FP) to have taken more than 
125% of their medication. Four other patients (two in 
each group) failed to record use of medication. When 
the data for morning and evening PEFR were 
re-analysed as per-protocol analyses, excluding these 
28 patients, there was still strong evidence of a 
treatment difference in favour of FP. At weeks 6-8, 
the treatment difference in mean morning PEFR 
expressed as % predicted was 7.0% points in favour 
of FP (99%CI 1.1-12.8; P=O.O022). Similarly, for 
evening PEFR, the treatment difference was 5.6% 
points in favour of FP (99% CI 1.2-10.0; P=O.OOll). 
Recruitment to the study was aimed at children 
with mild-moderate asthma who were being con- 
sidered for introduction of preventive therapy. No 
children entering the study had received SCG therapy 
or an inhaled corticosteroid in the past. It was 
notable, however, that the mean FEV, before enter- 
ing the trial was less than 80% of predicted and, 
during the 2 weeks of pre-treatment assessment, 
many children were experiencing symptoms which 
required bronchodilator therapy on most days. This 
emphasizes the importance of daily evaluation of 
symptoms, and the use of objective measurement of 
lung function when deciding on the need for regular 
treatment. 
Only a few small studies have compared SCG and 
inhaled corticosteroid treatment in childhood 
asthma. Three clinical trials comparing 4-week treat- 
ment periods and involving 40 children aged 7-15 
years (7), 20 children aged 613 years (8) and 24 
children aged 426 years (9) found an inhaled 
corticosteroid (betamethasone valerate or beclom- 
ethasone dipropionate) to be superior to SCG in 
terms of wheeze-free days and peak-flow rates 
recorded at home. The doses of inhaled corticoster- 
oid used in these studies, ranging from 400- 
8OOpg day- ‘, were much larger than that used in the 
present trial. The dose of FP given in this study 
corresponds to beclomethasone 200 fig day ~ ’ (22). 
One trial did not detect any difference in efficacy 
between SCG and beclomethasone dipropionate but 
the power to detect a difference was low because 
numbers were so small (14 subjects aged 5-15 years) 
(10). Two further studies in children with severe 
asthma suggested that substitution of an inhaled 
corticosteroid improves asthma in children who 
respond inadequately to treatment with SCG (11,12). 
At the time these studies were done, there was no 
long-term experience of the use of inhaled corti- 
costeroids in children and their use was largely 
confined to school-age children with severe asthma. It 
has since been shown that at these higher doses, it is 
possible to demonstrate some systemic effect on HPA 
axis (l-3). In a more recent study, Kraemer et al. 
found a greater improvement in lung mechanics and 
in non-specific bronchial reactivity in children given 
lOO-200,~g beclomethasone dipropionate three times 
daily, compared with those given 20 mg SCG three 
times daily for 8 weeks (13). None of the published 
studies have addressed the question of the relative 
speed of action of the drugs. It is interesting that in 
the present study there was evidence of a difference in 
treatment effect in favour of FP for morning PEFR 
during the first 2 weeks of the treatment period 
(Fig. la). 
No clinically serious, adverse events were reported 
with either drug but events resulting in withdrawal 
from the study were more frequent with SCG than 
with FP. Most of the adverse events were respiratory 
and seemed to indicate poor asthma control. Five 
children complained of retching, vomiting or an 
unpleasant taste after taking SCG by capsule powder 
device. The study period was short and no formal 
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assessment was made of adrenal axis function in the 
children taking FP. Studies of much longer duration 
with this new inhaled corticosteroid are needed 
before considering a change in the current recom- 
mendations for regular inhaled corticosteroid 
therapy in children with mild-moderate asthma. 
Nevertheless, the favourable results with FP in 
terms of efficacy and tolerability suggest that, in due 
course, it may be appropriate to lower the threshold 
for the administration of this inhaled corticosteroid 
to children, both in terms of age and severity of 
symptoms. 
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